ALS网络将支持协作研究工作

ALS网络将在加利福尼亚州劳伦斯·利弗莫尔国家实验室（Lawrence Livermore National Laboratory）上支持合作研究工作，该研究将使用电子健康记录（EHRS）来确定可能减慢肌萎缩性侧面硬化症（ALS）进展的现有药物。

The ALS Network will be supporting a collaborative research effort, at California’s Lawrence Livermore National Laboratory, that will use electronic health records (EHRs) to identify existing medications that could slow the progression of amyotrophic lateral sclerosis (ALS).

ALS网络将在加利福尼亚州劳伦斯·利弗莫尔国家实验室（Lawrence Livermore National Laboratory）上支持一项合作研究工作，该研究将使用电子健康记录（EHR）来确定可能减慢肌萎缩性侧向硬化症（ALS）进展的现有药物。

The $300,000 project is aimed at drug repurposing — finding medications already approved for other conditions that may have off-target effects beneficial in ALS. Because these therapies have well-established safety profiles, they could potentially be repurposed for use in ALS with less testing needed. That would allow these drugs to move more quickly through the development process for ALS than newly developed therapies.

这项耗资30万美元的项目旨在重新使用药物 - 发现已经批准了可能对ALS有益的其他靶向效果的药物。由于这些疗法具有完善的安全性概况，因此可能会重新使用用于较少测试的ALS。与新开发的疗法相比，这将使这些药物在ALS的开发过程中更快地移动。

The project will be led by Priyadip Ray, PhD, of Lawrence Livermore, as well as three other California-based researchers: Richard Reimer, MD, of Stanford University and Veterans Affairs; Jennifer Wilson, PhD, of the University of California, Los Angeles; and Kevin Grimes, MD, of Stanford University.

该项目将由劳伦斯·利弗莫尔（Lawrence Livermore）的Priyadip Ray博士领导，以及其他三名总部位于加利福尼亚的研究人员：斯坦福大学的理查德·雷默（Richard Reimer）和退伍军人事务；加利福尼亚大学洛杉矶分校的詹妮弗·威尔逊（Jennifer Wilson）博士；斯坦福大学的医学博士凯文·格莱姆斯（Kevin Grimes）。

“Medications typically have well-defined therapeutic targets, but often also have off-target effects,” Ray said in a press release from the ALS Network. “Our long-term goal is to identify associations between medications and progression of neurodegenerative diseases through the analysis of electronic health records. As an initial step, we have focused on ALS as a proof of principle study.”

雷在ALS网络的新闻稿中说：“药物通常具有明确定义的治疗靶标，但通常也具有脱靶效应。” “我们的长期目标是通过分析电子健康记录来确定药物与神经退行性疾病的进展之间的关联。作为第一步，我们将重点放在ALS上，作为主要研究的证明。”

Recommended Reading January 30, 2025 News by Andrea Lobo, PhD iPSC-derived microglia may help advance ALS research, therapies

推荐阅读2025年1月30日，Andrea Lobo的新闻，博士IPSC衍生的小胶质细胞可能有助于推进ALS研究，疗法

iPSC-derived microglia may help advance ALS research, therapies

IPSC衍生的小胶质细胞可能有助于进步ALS研究，疗法

US nonprofit contributes $35K for drug-repurposing research

美国非营利组织为毒品替代研究贡献了35,000美元

The ALS Network is providing about $35,000 in funding from its multifaceted research program for the study. Other funding will come from the ALS CURE Project, the Livermore Lab Foundation, the RDM Positive Impact Foundation, and Stanford University.

ALS网络从其多面研究计划中提供了约35,000美元的资金。其他资金将来自ALS Cure项目，Livermore Lab Foundation，RDM积极影响基金会和斯坦福大学。

“The ALS Network’s research-funding model is an ambitious program driven by urgency and innovation,” said Sheri Strahl, president and CEO of the ALS Network. “Providing funding to these experts will lead to greater discovery and progress critically needed to find better treatments and cures.”

ALS Network总裁兼首席执行官Sheri Strahl说：“ ALS网络的研究资金模型是由紧迫性和创新驱动的雄心勃勃的计划。” “向这些专家提供资金将导致更大的发现和进步，以找到更好的治疗方法和治疗方法。”

The collaborative project builds on a previous study that examined EHR data from more than 20,000 U.S. military veterans with ALS. Funded by the Livermore Lab Foundation with support from the ALS CURE Project, that research found several drugs and drug classes associated with longer survival in these patients.

该协作项目基于先前的研究，该研究检查了来自ALS的20,000多名美国退伍军人的EHR数据。由Livermore Lab Foundation资助，在ALS Cure项目的支持下，研究发现了几种与这些患者生存期更长有关的药物和药物类别。

However, veterans have characteristics that differ significantly from the general population, the researchers noted. For example, they are mostly male and with military experience — both known risk factors for ALS — and this may prevent findings from being generalized to other ALS patient groups.

但是，研究人员指出，退伍军人的特征与普通人群有很大不同。例如，它们主要是男性，并且具有军事经验 - 两者均是ALS的已知风险因素 - 这可能会阻止发现对其他ALS患者群体的推广。

Providing funding to these experts will lead to greater discovery and progress critically needed to find better treatments and cures.

向这些专家提供资金将导致更大的发现和进步，以找到更好的治疗方法和治疗方法。

To address that, researchers will use the Optum EHR dataset to assess data from a more diverse population of patients. Access to the database will be provided by Stanford, with machine learning tools from the Lawrence Livermore National Laboratory used to scan through the data and find potential drug candidates.

为了解决这个问题，研究人员将使用optum EHR数据集评估来自更多患者人群的数据。斯坦福大学将提供对数据库的访问，并提供来自劳伦斯·利弗莫尔国家实验室的机器学习工具，用于扫描数据并找到潜在的候选药物。

While the initial focus is on ALS, the RDM Positive Impact Foundation will also support similar efforts in Parkinson’s disease. Once the research techniques are established in ALS, the team will apply them to the same Optum EHR dataset to look for drugs that may slow Parkinson’s progression.

尽管最初的重点是ALS，但RDM阳性影响基础还将支持帕金森氏病的类似努力。一旦在ALS中建立了研究技术，该团队将将它们应用于相同的optum EHR数据集，以寻找可能减慢帕金森氏症进展的药物。

Ultimately, similarities across the two diseases may be used to accelerate the development of therapies for a broader range of neurodegenerative diseases, according to the researchers.

据研究人员称，最终，两种疾病之间的相似性可以用来加快针对更广泛的神经退行性疾病的疗法的发展。